BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Holdings Decreased by Bellevue Group AG

Bellevue Group AG decreased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 329,021 shares of the biotechnology company’s stock after selling 1,955 shares during the quarter. Bellevue Group AG’s holdings in BioMarin Pharmaceutical were worth $21,627,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Algert Global LLC acquired a new stake in BioMarin Pharmaceutical during the fourth quarter valued at approximately $2,767,000. AXA S.A. raised its position in shares of BioMarin Pharmaceutical by 1.6% during the 4th quarter. AXA S.A. now owns 571,538 shares of the biotechnology company’s stock valued at $37,567,000 after acquiring an additional 8,874 shares in the last quarter. Wahed Invest LLC raised its position in shares of BioMarin Pharmaceutical by 6.5% during the 4th quarter. Wahed Invest LLC now owns 4,881 shares of the biotechnology company’s stock valued at $321,000 after acquiring an additional 297 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in BioMarin Pharmaceutical by 121.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 18,103 shares of the biotechnology company’s stock worth $1,190,000 after purchasing an additional 9,915 shares during the period. Finally, PDT Partners LLC increased its stake in BioMarin Pharmaceutical by 168.4% during the fourth quarter. PDT Partners LLC now owns 88,663 shares of the biotechnology company’s stock valued at $5,828,000 after purchasing an additional 55,635 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now owns 16,955 shares of the company’s stock, valued at approximately $1,212,621.60. This represents a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on BMRN shares. Scotiabank raised their price target on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 20th. Royal Bank of Canada reissued a “sector perform” rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Oppenheimer raised BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price for the company in a report on Monday, February 24th. Citigroup cut their price target on BioMarin Pharmaceutical from $82.00 to $78.00 and set a “neutral” rating on the stock in a report on Friday. Finally, Piper Sandler boosted their price objective on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an “overweight” rating in a research report on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $92.95.

BioMarin Pharmaceutical Stock Down 1.1 %

Shares of BMRN stock opened at $62.03 on Friday. BioMarin Pharmaceutical Inc. has a 1 year low of $52.93 and a 1 year high of $94.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The business’s fifty day moving average is $65.84 and its 200-day moving average is $65.74. The stock has a market cap of $11.84 billion, a PE ratio of 28.20, a price-to-earnings-growth ratio of 0.61 and a beta of 0.27.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million for the quarter, compared to analysts’ expectations of $711.05 million. Equities analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.